Oxford Biomedica PLC
07 February 2005
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF
AMERICA, CANADA, AUSTRALIA OR JAPAN
Oxford BioMedica plc ('Oxford BioMedica' or the 'Company')
Termination of discussions
On 19 January 2005 the Board of Oxford BioMedica announced that it had received
an approach from a third party regarding a potential merger, which may or may
not lead to an offer for the Company.
The Board of Oxford BioMedica announces that the discussions that followed this
unsolicited approach have terminated.
7 February 2005
Enquiries:
Oxford BioMedica plc Tel: +44 (0) 1865 783000
Professor Alan Kingsman, Chief Executive Officer
Rothschild Tel: +44 (0) 20 7280 5000
Dr. Lynn Drummond
N M Rothschild & Sons Limited ('Rothschild'), which is authorised and regulated
by the Financial Services Authority in the United Kingdom, acts for Oxford
BioMedica plc and no one else in relation to the contents of this announcement
and will not be responsible to anyone other than Oxford BioMedica plc for
providing the protections afforded to clients of Rothschild nor for providing
advice in relation to the contents of this announcement.
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.